Mar 26, 2020

- Top-Line Results of a Phase 2b in Alzheimer’s On Track for Mid-Year 2020 - - Cash Balance Exceeds $26 Million at January 31, 2020 - - $5 Million Net Cash Use Expected in 2020 - AUSTIN, Texas , March 26, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.

Mar 25, 2020

Approximately 100 Study Participants Will Receive PTI-125 For 12 Months AUSTIN, Texas , March 25, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the initiation of an open-label extension study to